TY - JOUR
T1 - Theranostics in Neuroendocrine Tumors
T2 - Updates and Emerging Technologies
AU - Mallak, Nadine
AU - Yilmaz, Burcak
AU - Meyer, Catherine
AU - Winters, Celeste
AU - Mench, Anna
AU - Jha, Abhinav
AU - Prasad, Vikas
AU - Mittra, Erik
N1 - Publisher Copyright:
© 2024 Elsevier Inc.
PY - 2024/10
Y1 - 2024/10
N2 - Advancements in somatostatin receptor (SSTR) targeted imaging and treatment of well-differentiated neuroendocrine tumors (NETs) have revolutionized the management of these tumors. This comprehensive review delves into the current practice, discussing the use of the various FDA-approved SSTR-agonist PET tracers and the predictive imaging biomarkers, and elaborating on Lu177-DOTATATE peptide receptor radionuclide therapy (PRRT) including the evolving areas of post-therapy imaging practices, PRRT retreatment, and the potential role of dosimetry in optimizing patient treatments. The future directions sections highlight ongoing research on investigational PET imaging radiotracers, future prospects in alpha particle therapy, and combination therapy strategies.
AB - Advancements in somatostatin receptor (SSTR) targeted imaging and treatment of well-differentiated neuroendocrine tumors (NETs) have revolutionized the management of these tumors. This comprehensive review delves into the current practice, discussing the use of the various FDA-approved SSTR-agonist PET tracers and the predictive imaging biomarkers, and elaborating on Lu177-DOTATATE peptide receptor radionuclide therapy (PRRT) including the evolving areas of post-therapy imaging practices, PRRT retreatment, and the potential role of dosimetry in optimizing patient treatments. The future directions sections highlight ongoing research on investigational PET imaging radiotracers, future prospects in alpha particle therapy, and combination therapy strategies.
KW - dosimetry
KW - DOTATATE
KW - NETs
KW - somatostatin receptor
KW - theranostics
UR - http://www.scopus.com/inward/record.url?scp=85202868015&partnerID=8YFLogxK
U2 - 10.1016/j.currproblcancer.2024.101129
DO - 10.1016/j.currproblcancer.2024.101129
M3 - Article
C2 - 39232443
AN - SCOPUS:85202868015
SN - 0147-0272
VL - 52
JO - Current Problems in Cancer
JF - Current Problems in Cancer
M1 - 101129
ER -